A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Belly fat, also known as visceral fat, may contribute to brain atrophy and early markers of Alzheimer’s disease, new research ...

EXCLUSIVE: UCL researchers argue that loss of brain volume may in fact be a sign that the treatments are working.

"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

While brain shrinkage is usually an undesirable outcome, the team found that the excess volume loss was consistent across studies and correlated with how effective the therapy was in removing amyloid ...

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques ...

More information: Christopher R S Belder et al, Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy, The Lancet Neurology ...

COVID-19 may shrink the brain's gray matter, primarily in areas of the brain involved in smell and memory processing, a large ...